Farydak

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, pharmaand GmbH

Conditions

Multiple Myeloma

Phase 2

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

TerminatedNCT02720510

Novartis PharmaceuticalsMultiple Myeloma

Start: 2016-06-14End: 2017-05-22Updated: 2018-07-24

Unknown Phase

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

CompletedNCT04150289

pharmaand GmbHMultiple Myeloma

Start: 2019-11-04End: 2022-03-30Updated: 2023-06-15